

1 **Insulin resistance in thyroid disorders: association between anti-TPO and HOMA-IR**

2 Hari Krishnamurthy<sup>2\*</sup> Thushani Siriwardhane<sup>1</sup>, Karthik Krishna<sup>2</sup>, Qi Song<sup>2</sup>, Vasanth Jayaraman<sup>2</sup>,  
3 Tianhao Wang<sup>2</sup>, Kang Bei<sup>2</sup>, John J. Rajasekaran<sup>2</sup>

4 <sup>1</sup> Vibrant America LLC., San Carlos, CA, USA

5 <sup>2</sup> Vibrant Sciences LLC., San Carlos, CA, USA

6 Running title: Insulin resistance in thyroid disorders

7 Address correspondence to: Hari Krishnamurthy, Vibrant Sciences LLC., 1021 Howard Avenue,  
8 Suite B, San Carlos, CA 94070, USA. Phone: 1-866-364-0963, Fax: 1-650-508-8262. E-mail:  
9 hari@vibrantsci.com

10 Thushani Siriwardhane: thushanis@vibrant-america.com

11 Vasanth Jayaraman: vasanth.jayaraman@vibrantsci.com

12 Karthik Krishna: karthik@vibrantsci.com

13 Qi Song: qsong@vibrant-america.com

14 Tianhao Wang: tianhao.wang@vibrantsci.com

15 Kang Bei: kang@vibrantsci.com

16 John J. Rajasekaran: jjrajasekaran@vibrantsci.com

17

18 **ABSTRACT**

19 The association of thyroid disease and diabetes has been classically described. However, the  
20 comorbidity of thyroid disparities and insulin resistance is not frequently assessed, especially the  
21 sequence of the occurrence of these markers. We performed a retrospective analysis to evaluate  
22 the association between thyroid disease and diabetes markers. We further investigated the  
23 sequence of occurrence of thyroid and diabetes markers to identify any predictive capabilities of  
24 these markers. We evaluated 32787 subjects who were classified based on their serum thyroid  
25 hormones and autoantibody levels. Our general prevalence results showed that HOMA-IR was  
26 elevated in overt hypothyroid subjects (43.7%) and overt hyperthyroid subjects (42.2%). HbA1C  
27 was elevated in subclinical hypothyroid subjects (19.2%), overt hypothyroid subjects (22.3%)  
28 and overt hyperthyroid subjects (21.2%). Glucose was significantly elevated in subclinical  
29 hypothyroid subjects (24.2%) and overt hyperthyroid subjects (31.0%). Insulin was only

30 significantly elevated in overt hypothyroid subjects (15.1%). Interestingly, we found that 70.3%  
31 of subjects who had their HOMA-IR score escalated from negative (HOMA-IR<2.7) to positive  
32 (HOMA-IR>2.7) during their multiple visits had anti-TPO 369 ( $\pm 242$ ) days prior to the onset of  
33 this change. Our comprehensive study provided evidence that the presence of anti-TPO may  
34 suggest a predictive role in developing insulin resistance later in life.

35 **Key Words:** HOMA-IR, Hyperthyroidism, Hypothyroidism, Anti-TPO, Insulin Resistance

36 **Strengths and limitations of the study:**

- 37 • The strength of our study is the large population size including a larger set of markers
- 38 from both thyroid disease and diabetes.
- 39 • The limitation in our study is the distorted male and female ratio.

40

41 **INTRODUCTION**

42 Thyroid hormones exert a fine balance in glucose metabolism, acting as both an insulin agonist  
43 and an antagonist in different organs. An imbalance, a deficit, or an excess of thyroid hormones  
44 could cause disequilibria leading to different disorders, especially in carbohydrate metabolism  
45 and insulin resistance.<sup>1</sup> Thyroid diseases and diabetes are the two most common endocrine  
46 disorders encountered in clinical practice. Thyroid disease is mainly classified into  
47 hypothyroidism and hyperthyroidism. Elevated levels of thyroid hormones are seen in  
48 hyperthyroidism while low levels of thyroid hormones are prevalent in hypothyroidism. Insulin  
49 resistance is a condition either caused by defects in insulin production by pancreatic  $\beta$ -cells or  
50 defects in effectively employing its function in target cells leading to diabetes. The prevalence of  
51 thyroid disease in patients with diabetes is significantly increased than that in the general  
52 population. A study conducted by Perros et al. demonstrated a prevalence of 31.4% of thyroid  
53 disease in type 1 female diabetes and 6.9% in type 2 male diabetes.<sup>2</sup> In addition to diabetes,  
54 studies have indicated a possible relationship between thyroid status and insulin sensitivity.  
55 Though the results of the studies on the effect of thyroid dysfunction on insulin resistance are  
56 controversial, many studies have shown that hyperthyroidism may cause impaired glucose  
57 tolerance leading to hepatic insulin resistance while hypothyroidism may cause insulin resistance  
58 in peripheral tissues.<sup>3</sup> Additionally, insulin resistance and autoimmune thyroid disease have  
59 shown to mutually influence each other. Studies have reported positive connections between  
60 thyroid autoantibodies and insulin resistance.<sup>4-6</sup> Most of these studies have utilized the  
61 Homeostatic model assessment (HOMA) method to evaluate the insulin resistance of individuals.

62 HOMA-IR (HOMA-insulin resistance) is a mathematical model for assessing  $\beta$ -cell function and  
63 insulin resistance from fasting glucose and insulin. The HOMA-IR score is determined from  
64 glucose and insulin levels in blood in baseline/fasting conditions. In HOMA-IR score, the plasma  
65 glucose and insulin concentrations were reflecting the hepatic and peripheral glucose efflux and

66 uptake, while decreases in  $\beta$ -cell function were modeled by changing the  $\beta$ -cell response to  
67 plasma glucose concentrations.<sup>7,8</sup> The HOMA-IR has proven to be a robust tool for the surrogate  
68 assessment of insulin resistance.

69 Previous studies have suggested a close correlation between insulin resistance and thyroid  
70 autoantibodies. However, studies to evaluate the sequence of occurrence of each marker have not  
71 been performed. Anti-TPO has been shown to precede years before the onset of many diseases,  
72 such as autoimmune thyroid disease, connective tissue disorders, etc.<sup>9-11</sup> In the present study, we  
73 first investigated the prevalence of diabetes markers in thyroid disease individuals and then  
74 explored the sequential occurrence of thyroid autoantibodies, anti-TPO, and anti-Tg in relation to  
75 HOMA-IR score changes. Understanding the sequential occurrence of these biomarkers will not  
76 only help to recognize the disease pathogenesis but also may help for disease prognosis to  
77 identify at-risk individuals.

## 78 **MATERIALS AND METHODS**

### 79 **Study Design and Population**

80 A total of 32787 subjects who had suspected thyroid disease or related conditions were tested for  
81 thyroid panel and diabetes markers at the Vibrant America Clinical Laboratory by the standard  
82 thyroid panel and the diabetes panel between January 2015 and June 2019. Subjects were  
83 characterized based on their serum thyroid markers as subclinical hypothyroidism, overt  
84 hypothyroidism, subclinical hyperthyroidism, overt hypothyroidism, and controls (thyroid  
85 hormones in range). The clinical information on the majority of these patients was provided by  
86 physicians as ICD-10-CM (International Classification of Diseases, Tenth Revision, Clinical  
87 Modification) codes. The percentage distribution of the top 20 ICD-10-CM codes reported is  
88 listed in table S1. This cohort was subdivided into single visit subjects (only visited once  
89 between January 2015 and June 2019) and multiple visit subjects (three or more visits between  
90 January 2015 and June 2019) for different analysis purposes.

### 91 **Thyroid Panel**

92 TSH, FT4, anti-TPO, and anti-Tg were measured using the commercial Roche e601 analyzer  
93 (Roche Diagnostics, Indianapolis, IN, USA) according to the manufacturer's recommendations.  
94 All reagents were purchased from Roche Diagnostics (Indianapolis, IN, USA). Human serum  
95 specimens were used on Elecsys immunoassay analyzers. Elecsys TSH assay was based on  
96 specific TSH monoclonal antibodies specifically directed against human. The antibodies labeled  
97 with a ruthenium complex consist of a chimeric construct from human- and mouse-specific  
98 components. As a result, interfering effects due to HAMA (human anti-mouse antibodies) were  
99 largely eliminated. The Elecsys FT4 test employed a specific anti-T4 antibody labeled with a  
100 ruthenium complex to determine the free thyroxine. The Elecsys T3 assay employs polyclonal  
101 antibodies specifically directed against T3. Endogenous T3, released by the action of 8-anilino-1-  
102 naphthalene sulfonic acid (ANS), competes with the added biotinylated T3-derivative for the

103 binding sites on the antibodies labeled with the ruthenium complex. In the Elecsys FT3 test the  
104 determination of free triiodothyronine is made with the aid of a specific anti-T3 antibody labeled  
105 with a ruthenium complex. The Elecsys T4 assay employs an antibody specifically directed  
106 against T4. Endogenous T4, released by the action of 8-anilino-1-naphthalene sulfonic acid  
107 (ANS), competes with the added biotinylated T4-derivative for the binding sites on the  
108 antibodies labeled with the ruthenium complex. RT3 was measured using LC-MS on the Xevo  
109 TQ-XS mass spectrometer. Elecsys anti-TPO assay employed recombinant antigens and  
110 polyclonal anti-TPO antibodies whereas Elecsys anti-Tg assay employed monoclonal human  
111 anti-Tg antibodies.

## 112 **Reference Ranges for Thyroid Markers**

113 Thyroid hormone reference ranges are subject to the lab where the test is performed. In this  
114 study, we followed the reference ranges that majority of the labs used. The reference range of  
115 hormones and autoantibody levels in a healthy control used in this study are shown in table 1.  
116 Subclinical hypothyroidism, subclinical hyperthyroidism, overt hypothyroidism and overt  
117 hyperthyroidism were attributed using these ranges.

118 The categorization of thyroid disease status by evaluating TSH and FT4 levels used in this study  
119 is shown in table 2.

120

## 121 **Diabetes Panel**

122 The Diabetes panel consist of HbA1C, ADIP, Glucose, Glymark, GSP, Insulin. The HbA1c  
123 determination was based on the turbidimetric inhibition immunoassay (TINIA) for hemolyzed  
124 whole blood. The glucose assay was based on the enzymatic reference method with hexokinase.  
125 Hexokinase catalyzed the phosphorylation of glucose to glucose-6-phosphate by ATP. Glucose-  
126 6-phosphate dehydrogenase oxidized glucose-6-phosphate in the presence of NADP to  
127 gluconate-6-phosphate. No other carbohydrate was oxidized. The rate of NADPH formation  
128 during the reaction was directly proportional to the glucose concentration and was measured  
129 photometrically. The diazyme insulin assay was used to determine insulin in serum samples.  
130 Latex particles coated with antibody specific to human insulin was used to react with insulin  
131 present in the sample. Immunoturbidimetry was using Beckman Counter AU series analyzer  
132 (Beckman Coulter, Inc., Georgia, USA) was used to measure the turbidity at 600nm primary and  
133 800 nm secondary. The Glycated serum protein assay used proteinase K to digest GSP into low  
134 molecular weight glycated protein fragments and used diazyme's specific fructosaminase. The  
135 colorimetric product was measured at 546-600 nm. ADIP assay was based on adiponectin and  
136 anti-adiponectin coated latex complexation. The turbidity of the antibody-antigen complex was  
137 measured at 570 nm via Roche Cobas 6000 c501 (Roche Diagnostics, Indiana, USA).

## 138 **HOMA-IR Calculation**

139 HOMA-IR was calculated as:

140 
$$\text{HOMA-IR} = [\text{Fasting Plasma Glucose (mg/dl)} \times \text{Fasting Insulin}(\mu\text{U/ml})] / 405$$

### 141 **Patient and Public Involvement**

142 This study does not include any patient or public involvement and is based on retrospective  
143 analysis of de-identified laboratory data. IRB exemption (work order #1-1098539-1) was  
144 determined by the Western Institutional Review Board (WIRB) for Vibrant America  
145 Biorepository to use de-linked and de-identified remnant human specimen and medical data for  
146 research purposes.

### 147 **Statistical Analysis**

148 The data were analyzed using Java for Windows version 1.8.161 and R for Windows version  
149 3.5.0. Data were expressed as mean  $\pm$  standard deviation (SD). The association between PSA  
150 and autoimmune markers and controls were tested using nonparametric chi-square test with 95%  
151 confidential interval. P value < 0.05 was considered statistically significant.

## 152 **RESULTS**

### 153 **Patient Clinical Characteristics**

154 A total of 32787 subjects who ordered the thyroid panel and the diabetes panel were included in  
155 this retrospective study. Table 3 shows the demographics of thyroid positive subjects (different  
156 thyroid diseases based on their serum thyroid hormone levels) and negative controls in this  
157 study.

### 158 **Prevalence of Diabetes markers in thyroid disease**

159 To evaluate the general prevalence of diabetes markers in thyroid disease subjects, we first  
160 assessed single visit subjects who had tested for both thyroid disease and diabetes markers  
161 (HOMA-IR, HbA1C, ADIP, Glucose, Glymark, GSP, Insulin). Figure 1 shows the diabetes  
162 markers significantly elevated in different thyroid disease subjects grouped as subclinical  
163 hypothyroidism, overt hypothyroidism, subclinical hyperthyroidism, overt hyperthyroidism  
164 based on their serum TSH and FT4 levels. HOMA-IR was elevated in overt hypothyroid subjects  
165 (171/391, 43.7%) and overt hyperthyroid subjects (129/306, 42.2%) compared to its controls, the  
166 thyroid negative group (10763/28896, 37.2%). HbA1C was elevated in subclinical hypothyroid  
167 subjects (639/3325, 19.2%), overt hypothyroid subjects (137/614, 22.3%) and overt hyperthyroid  
168 subjects (101/476, 21.2%) compared to its controls (7237/44829, 16.1%). Glucose was  
169 significantly elevated in subclinical hypothyroid subjects (579/2394, 24.2%) and overt  
170 hyperthyroid subjects (106/342, 31.0%) compared to its control (6984/31803, 22%). Insulin was  
171 only significantly elevated in overt hypothyroid subjects (72/478, 15.1%) compared to its control  
172 (4022/35197, 11.4%). Subclinical hyperthyroidism did not a show significant relationship with  
173 any of the diabetes markers.

174 Next, we tested the prevalence of these diabetes markers in antibodies (Anti TPO, Anti Tg) and  
175 individual thyroid hormones (TSH, FT4, FT3, RT3, T3, T4). Table 4 provides the prevalence of  
176 diabetes markers in subjects with elevated thyroid autoantibodies. HOMA-IR score was elevated  
177 in subjects seropositive to anti-TPO and anti-Tg. High insulin levels were seen in subjects with  
178 anti-TPO positivity. The prevalence of diabetes markers in subjects with elevated/reduced levels  
179 of individual thyroid hormones are listed in table S2.

180

### 181 **Early detection of anti-TPO antibodies predicted HOMA-IR score change**

182 To evaluate the direction of disease correlation between diabetes and thyroid disease we  
183 extracted subjects who had multiple visits during the time of the study (January 2015 to June  
184 2019). First, a sub cohort who had HOMA-IR<2.7 (negative) in their initial test but increased  
185 over time (HOMA-IR>2.7-positive) during their subsequent visits were selected to analyze their  
186 clinical profiles to identify any predictive markers for insulin resistance. A total of 155 subjects  
187 was included in this group. As shown in figure 2, 109/155 (70.3%) had anti-TPO 369 ( $\pm$  242)  
188 days (ranging from 55 days to 1229 days) prior to the onset of HOMA-IR change from negative  
189 to positive. It was significantly different from control group which had 46/155 (29.7%) subjects  
190 with either no anti-TPO presence or anti-TPO on or after the negative HOMA-IR change to  
191 positivity. Anti-Tg (56/155, 36.1%) or any thyroid disease profile (subclinical hypothyroidism-  
192 8/155, 5.2%, overt hypothyroidism- 2/155, 1.3%, subclinical hyperthyroidism-12/155, 7.7%,  
193 overt hypothyroidism- 2/155, 1.3%) did not show this predictive behavior. Next, we analyzed the  
194 early occurrence of HOMA-IR positivity in subjects who have converted from seronegative to  
195 seropositive for anti-TPO, anti-Tg and thyroid profiles to identify whether high HOMA-IR  
196 scores could predict thyroid disease. Of 206 subjects, 36 (17.5%) had HOMA-IR positivity  
197 before the onset of anti-TPO seropositivity. Moreover, 13/70 (18.6%) subjects only had HOMA-  
198 IR positivity before the onset of thyroid disease and 16/64 (25.0%) had HOMA-IR change prior  
199 to the onset of anti-Tg negativity. These data did not show any significant relationship with  
200 HOMA-IR positivity occurring ahead of either anti-TPO, anti-Tg or thyroid disease.

201

## 202 **DISCUSSION**

203 Our study is the first in the literature evaluating the sequence of markers occurring in thyroid  
204 disease and insulin resistance comorbidity. Patients with thyroid disparities are known to have  
205 glucose and insulin metabolism disorders, however, none of the studies have elucidated the  
206 disease marker sequence. The direction of disease correlation is important for effective follow-up  
207 testing and treatment strategies for at-risk subjects.

208 To understand the general prevalence, we first evaluated the association between thyroid disease  
209 and diabetes markers in single visit subjects. We evaluated thyroid disease profiles categorized  
210 based on their serum TSH and FT4 levels. We found that both overt hypothyroidism and overt

211 hyperthyroidism had elevated levels of HOMA-IR. HbA1C was elevated in subclinical  
212 hypothyroidism, overt hypothyroidism and overt hyperthyroidism. Glucose was elevated in both  
213 subclinical hypothyroidism and overt hyperthyroidism and insulin is only elevated in overt  
214 hypothyroidism. Clinical hyperthyroidism is associated with abnormal glucose tolerance and  
215 insulin resistance.<sup>12</sup> Specifically, overt hyperthyroidism has increased demand for insulin which  
216 is often due to accelerated metabolism, tissue resistance to insulin, and elevated insulin  
217 degradation.<sup>3</sup> Many theories have established to explain the peripheral insulin resistance in  
218 hyperthyroidism. Some studies show that increased secretion of adiponectin such as interleukin-  
219 6, and TNF-  $\alpha$  in hyperthyroid patients may be related to the development of insulin resistance.<sup>14</sup>  
220 Another mechanism by which thyroid hormones increase hepatic glucose production is through  
221 the increased expression of GLUT2 transporter on hepatic plasma membrane which was found to  
222 be twice as high in hyperthyroid patients compared to hypothyroid patients.<sup>1</sup> There are  
223 comparatively lesser human studies conducted to evaluate the association between  
224 hypothyroidism and insulin resistance. In hypothyroidism, it is speculated that decreased  
225 intestinal glucose absorption rate and decreased adrenergic activity may lead to a reduction in  
226 glycogenolysis in the liver and muscles and gluconeogenesis that could further decrease the  
227 baseline insulin secretion.<sup>12, 15</sup> Our results indicated a significant prevalence of increased  
228 HOMA-IR scores in hypothyroid subjects indicating a possible insulin resistance. Similar results  
229 were also seen by other groups where they found hypothyroidism induced a decrease in the  
230 insulin-mediated glucose disposal that reverted upon treatment.<sup>16-18</sup>

231 Autoimmune thyroid disease and insulin resistance are two chronic inflammatory diseases.  
232 Hence, we evaluated the relationship between subjects that were seropositive for thyroid  
233 autoantibodies and insulin resistance. Our results showed that subjects with thyroid antibodies,  
234 anti-TPO and anti-Tg had significantly elevated HOMA-IR scores compared to their respective  
235 control groups. Moreover, seropositive subjects for anti-TPO had elevated insulin levels  
236 compared to seronegative subjects. Studies have shown a connection between anti-TPO titer, the  
237 secretory function of monocytes, lymphocytes and pro-inflammatory cytokines such as TNF- $\alpha$   
238 and IL-6.<sup>19</sup> These monocytes, lymphocytes and their secretory cytokines TNF- $\alpha$  and IL-6 are also  
239 responsible for developing insulin resistance.<sup>20</sup> Our results were consistent with Tina Mazaheri et  
240 al. where they found significantly high insulin levels in subjects with anti TPO antibodies more  
241 than 1000 IU/ml.<sup>21</sup> However, their HOMA-IR score did not show any significant difference.

242 It has long been a topic of controversy about the direction of the effect of insulin resistance and  
243 autoimmune thyroid disease on each other. To our knowledge, none of the studies have evaluated  
244 the direction of these two comorbid diseases, diabetes and thyroid disease. To assess the  
245 sequence of occurrence of these disease markers, we evaluated the predictive characteristics of  
246 anti-TPO, anti Tg, and thyroid disease in insulin resistance and vice versa. Interestingly, we  
247 found that 70.3% subjects had anti-TPO prior to the HOMA-IR change from negative to positive,  
248 indicating a possible predictive role of anti-TPO in insulin resistance. None of the thyroid  
249 disease profiles (15.5%) nor anti-Tg (36.1%) preceded the HOMA-IR score change, indicating

250 that thyroid disease profiles or anti-Tg does not contain any significant predictability on insulin  
251 resistance. However, the opposite direction, the appearance of insulin resistance, in terms of  
252 high HOMA-IR scores, appearing before anti-TPO positivity, anti-Tg positivity or any thyroid  
253 disease positivity did not provide any significant results, eliminating the hypothesis of the  
254 occurrence of insulin resistance before anti-TPO, anti-Tg or thyroid disease seropositivity.

255 In this study, we mainly examined the effect of direction of comorbid diseases, thyroid disease  
256 and insulin resistance. The primary strength of our study is the large population size including a  
257 larger set of markers from both thyroid disease and diabetes. However, a limitation in our study  
258 is the distorted male and female ratio. A study with similar male and female ratio with all-  
259 inclusive clinical characteristics such as thyroid treatments, female menopausal status, etc. would  
260 be required to extrapolate the results to eventually achieve a generalized outcome. In conclusion,  
261 we showcased that thyroid autoantibody, anti-TPO precedes the changes in insulin resistance in  
262 terms of HOMA-IR score changes from negative to positive, thus anti-TPO could eventually be  
263 used as a predictive marker for disease stratification.

#### 264 **Consent for Publication**

265 N/A

#### 266 **Availability of data and material**

267 The raw data supporting the conclusions of this manuscript will be made available by the  
268 corresponding author on reasonable request.

#### 269 **Competing interests**

270 The authors have read the journal's policy and the authors of this manuscript have the following  
271 competing interests: TS and QS are paid employees of Vibrant America LLC. KK, VJ, TW, KB,  
272 HK, JJR, are paid employees of Vibrant Sciences LLC. Vibrant Sciences or Vibrant America  
273 could benefit from increased testing based on the results. There are no patents, products in  
274 development, or marketed products to declare.

#### 275 **Funding**

276 Vibrant America provided funding for this study in the form of salaries for authors [TS, QS, KK,  
277 VJ, TW, KB, HK, JJR]. The funders had no role in study design, data collection and analysis,  
278 decision to publish, or preparation of the manuscript.

279

#### 280 **Author contributions**



281 Conception and study design: HK, JR, VJ. Performing experiments: KK, TW. Analysis and  
282 interpretation: TS, KB, QS, HK. Manuscript preparation: TS, HK. All authors read and approved  
283 the final manuscript.

## 284 **Acknowledgement**

285 We acknowledge Vibrant America LLC for supporting this research.

## 286 **Ethics approval and consent to participate**

287 The study was conducted under the ethical principles that have their origins in the Declaration of  
288 Helsinki. This is a retrospective study conducted from remnant samples of individuals that  
289 visited Vibrant Clinical Lab for routine tests. The IRB (WCG IRB (Western Institutional Review  
290 Board) (#1-1098539-1)) exemption enabled us to use the de-identified laboratory data for the  
291 retrospective analysis. The data and materials in this manuscript have not been published  
292 elsewhere and are not under consideration by another journal.

293

## 294 **REFERENCES**

295

- 296 1. Brenta G. Why Can Insulin Resistance Be a Natural Consequence of Thyroid  
297 Dysfunction? *Journal of Thyroid Research*. 2011; 2011.
- 298 2. Perros P, McCrimmon RJ, Shaw G and Frier BM. Frequency of thyroid dysfunction in  
299 diabetic patients: value of annual screening. *Diabet Med*. 1995; 12: 622-7.
- 300 3. Gierach M, Gierach J and Junik R. Insulin resistance and thyroid disorders. *Endokrynol*  
301 *Pol*. 2014; 65: 70-6.
- 302 4. Barker JM, Yu J, Yu L, et al. Autoantibody "subspecificity" in type 1 diabetes: risk for  
303 organ-specific autoimmunity clusters in distinct groups. *Diabetes Care*. 2005; 28: 850-5.
- 304 5. Kordonouri O, Maguire AM, Knip M, et al. Other complications and associated  
305 conditions with diabetes in children and adolescents. *Pediatr Diabetes*. 2009; 10 Suppl 12: 204-  
306 10.
- 307 6. Holl RW, Bohm B, Loos U, Grabert M, Heinze E and Homoki J. Thyroid autoimmunity  
308 in children and adolescents with type 1 diabetes mellitus. Effect of age, gender and HLA type.  
309 *Horm Res*. 1999; 52: 113-8.
- 310 7. Chang AM, Smith MJ, Bloem CJ, Galecki AT, Halter JB and Supiano MA. Limitation of  
311 the Homeostasis Model Assessment to Predict Insulin Resistance and  $\beta$ -Cell Dysfunction in  
312 Older People. *The Journal of Clinical Endocrinology & Metabolism*. 2006; 91: 629-34.
- 313 8. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF and Turner RC.  
314 Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma  
315 glucose and insulin concentrations in man. *Diabetologia*. 1985; 28: 412-9.

- 316 9. Hutfless S, Matos P, Talor MV, Caturegli P and Rose NR. Significance of prediagnostic  
317 thyroid antibodies in women with autoimmune thyroid disease. *J Clin Endocrinol Metab.* 2011;  
318 96: E1466-71.
- 319 10. Siriwardhane T, Krishna K, Ranganathan V, et al. Significance of Anti-TPO as an Early  
320 Predictive Marker in Thyroid Disease. *Autoimmune Diseases.* 2019; 2019: 6.
- 321 11. Siriwardhane T, Krishna K, Ranganathan V, et al. Exploring Systemic Autoimmunity in  
322 Thyroid Disease Subjects. *Journal of Immunology Research.* 2018; 2018: 7.
- 323 12. Maratou E, Hadjidakis DJ, Kollias A, et al. Studies of insulin resistance in patients with  
324 clinical and subclinical hypothyroidism. *Eur J Endocrinol.* 2009; 160: 785-90.
- 325 13. Donckier J. Endocrine diseases and diabetes. In: Pickup J and Williams G, (eds.).  
326 *Textbook of diabetes.* Blackwell Publishing, 2003, p. 27.1–.15.
- 327 14. Mitrou P, Boutati E, Lambadiari V, et al. Insulin resistance in hyperthyroidism: the role  
328 of IL6 and TNF $\alpha$ . 2010; 162: 121.
- 329 15. Dimitriadis G, Mitrou P, Lambadiari V, et al. Insulin Action in Adipose Tissue and  
330 Muscle in Hypothyroidism. *The Journal of Clinical Endocrinology & Metabolism.* 2006; 91:  
331 4930-7.
- 332 16. ROCHON C, TAUVERON I, DEJAX C, et al. Response of glucose disposal to  
333 hyperinsulinaemia in human hypothyroidism and hyperthyroidism. *Clinical Science.* 2003; 104:  
334 7-15.
- 335 17. Stanicka S, Vondra K, Pelikanova T, Vlcek P, Hill M and Zamrazil V. Insulin sensitivity  
336 and counter-regulatory hormones in hypothyroidism and during thyroid hormone replacement  
337 therapy. *Clin Chem Lab Med.* 2005; 43: 715-20.
- 338 18. Handisurya A, Pacini G, Tura A, Gessl A and Kautzky-Willer A. Effects of T4  
339 replacement therapy on glucose metabolism in subjects with subclinical (SH) and overt  
340 hypothyroidism (OH). *Clinical Endocrinology.* 2008; 69: 963-9.
- 341 19. Nielsen CH, Brix TH, Leslie RG and Hegedus L. A role for autoantibodies in  
342 enhancement of pro-inflammatory cytokine responses to a self-antigen, thyroid peroxidase. *Clin*  
343 *Immunol.* 2009; 133: 218-27.
- 344 20. Wei Y, Chen K, Whaley-Connell AT, Stump CS, Ibdah JA and Sowers JR. Skeletal  
345 muscle insulin resistance: role of inflammatory cytokines and reactive oxygen species. *Am J*  
346 *Physiol Regul Integr Comp Physiol.* 2008; 294: R673-80.
- 347 21. Mazaheri T, Sharifi F and Kamali K. Insulin resistance in hypothyroid patients under  
348 Levothyroxine therapy: a comparison between those with and without thyroid autoimmunity. *J*  
349 *Diabetes Metab Disord.* 2014; 13: 103.




Figure 1. Prevalence of diabetes markers in subjects with different thyroid disease profiles compared to their controls (thyroid disease negative). Diabetes markers significantly elevated/reduced are only shown.




Figure 2. The prevalence of different thyroid diseases, anti-TPO, and anti-Tg prior to the onset of HOMA-IR elevation compared to their respective control groups. Thyroid control group consists of subjects who had thyroid disease-parallel, thyroid disease-following, and no thyroid disease to the onset of HOMA elevation. Anti-TPO control group consists of subjects who had anti-TPO-parallel, anti-TPO -following, and no anti-TPO to the onset of HOMA elevation. Anti-Tg control group consists of subjects who had anti-Tg-parallel, anti-Tg-following, and no anti-Tg to the onset of HOMA elevation.

Table 1. Reference ranges for thyroid markers studied

Marker	Reference Range
TSH	0.3-4.2 mIU/L
FT4	0.9-1.7 ng/dL
Anti- TPO	<9.0 IU/mL
Anti-Tg	<4.0 IU/mL

Table 2. Thyroid disease categorization

Disease Condition	TSH	FT4
Subclinical hypothyroidism	> 4.2 mIU/L	0.9-1.7 ng/dL
Subclinical hyperthyroidism	< 0.3 mIU/L	0.9-1.7 ng/dL
Overt hypothyroidism	> 4.2 mIU/L	< 0.9 ng/dL
Overt hyperthyroidism	< 0.3 mIU/L	> 1.7 ng/dL
Thyroid Disease negative	0.3-4.2 mIU/L	0.9-1.7 ng/dL

Table 3. Demographics of subjects with different thyroid disease profiles.

	Subclinical Hypothyroidism	Overt Hypothyroidism	Subclinical Hyperthyroidism	Overt Hyperthyroidism	Thyroid-(Control)
N	3455/52662 (6.6%)	637/52662 (1.2%)	1626/52662 (3.1%)	494/52662 (0.9%)	46450/52662 (88.2)
Gender	1258M/2197F	134M/503F	168M/1458F	72M/422F	16812M/29638F
Age	50.0M/48.2F	53.4M/51.3F	55.8M/52.5F	52.9M/53.0F	47.1M/45.6F

Table 4. Prevalence of diabetes markers in subjects with elevated thyroid autoantibodies.

	Anti TPO+	Anti TPO-	P Value	Anti Tg+	Anti Tg-	P Value
HOMA-IR Positive	<b>45.5%</b> <b>(1869/4104)</b>	<b>37.5%</b> <b>(11015/29387)</b>	<b>&lt;0.0001</b>	<b>41.1%</b> <b>(1747/4255)</b>	<b>37%</b> <b>(8285/22364)</b>	<b>&lt;0.0001</b>
High HbA1C	16.3% (990/6076)	15.4% (6502/42088)	0.0930	14% (872/6210)	14.7% (4701/32057)	0.2100
Low ADIP	2.2% (94/4184)	3.1% (918/29592)	0.0028	1.7% (74/4391)	3% (671/22699)	<0.0001
High Glucose	22.1% (1001/4525)	22% (7097/32218)	0.9022	19.8% (908/4595)	21.5% (5186/24139)	0.0093
Low Glucose	1.7% (75/4525)	1.8% (567/32218)	0.6659	1.8% (84/4595)	1.9% (463/24139)	0.7262
Low Glymark	10.3% (314/3058)	10.1% (2250/22345)	0.7564	8.6% (259/2998)	10.1% (1509/14881)	0.0132
GSP	10.7% (438/4104)	10.7% (3159/29601)	1.0000	11.3% (476/4215)	11.4% (2540/22266)	0.8507
High Insulin	<b>14.1%</b> <b>(266/1888)</b>	<b>11.5%</b> <b>(4490/39169)</b>	<b>0.0006</b>	11.2% (588/5238)	11.1% (2990/26991)	0.7735
Low Insulin	2.9% (144/5005)	2.8% (986/34815)	0.8936	2.8% (149/5238)	2.8% (764/26991)	0.9916